Frontotemporal Dementia clinical trials

Explore recruiting frontotemporal dementia clinical trials.

Recruiting frontotemporal dementia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Frontotemporal Dementia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A study to find how well VES001 works and how safe it is in participants with GRN -frontotemporal dementia (GRN-FTD) showing no symptoms

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension

Netherlands, Belgium, Spain, France, Portugal, Italy +1 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)

France, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Open-Label, Ascending Dose, Multicentre Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Sweden, Spain, Belgium, Netherlands, Italy, Poland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

SAD and MAD study of VES001

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

Greece, Germany, Belgium, Italy, Sweden, Portugal +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Frontotemporal Dementia trials by city

Frontotemporal Dementia in Toronto Frontotemporal Dementia in Vancouver Frontotemporal Dementia in Montreal Frontotemporal Dementia in Calgary Frontotemporal Dementia in Edmonton Frontotemporal Dementia in Ottawa Frontotemporal Dementia in Winnipeg Frontotemporal Dementia in Quebec City Frontotemporal Dementia in Hamilton Frontotemporal Dementia in Kitchener Frontotemporal Dementia in London Frontotemporal Dementia in Halifax Frontotemporal Dementia in New York Frontotemporal Dementia in Los Angeles Frontotemporal Dementia in Chicago Frontotemporal Dementia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease